Genflow Biosciences PLC Non-Dilutive Grant Research Award (4141C)
11 October 2022 - 5:00PM
UK Regulatory
TIDMGENF
RNS Number : 4141C
Genflow Biosciences PLC
11 October 2022
PRESS RELEASE
11 October 2022
Genflow Biosciences Plc
("Genflow" or "the Company")
Genflow Research Programme conducted with IVEX Lab Receives
Non-Dilutive Grant Worth Quarter of a Million Euros from Enterprise
Estonia
Genflow (LSE: GENF) is pleased to announce that its
adeno-associated virus ("AAV") research and development programme
in Estonia, operated in collaboration with IVEX lab OÜ ("IVEX"), an
Estonian company specialising in the research and development of
biotechnology therapeutics, has received a non-dilutive grant award
of EUR250,000 from the Applied Research Programme of Enterprise
Estonia, an Estonian governmental institution designed to stimulate
business growth in the country.
The research and development programme is a collaborative
project between Genflow and IVEX focused on the development of an
anti-aging gene therapy platform designed to target nearly 100
million patients worldwide who suffer from Werner's syndrome,
non-alcoholic fatty liver disease ("NAFLD"), and non-alcoholic
steatohepatitis, an advanced form of NAFLD, as well as other major
clinical disorders.
IVEX, which is a leading biotech that has partnered with the
largest universities in Estonia: Tallinn University of Technology
and University of Tartu, is a strategic partner for Genflow. In
April 2021, Genflow BE entered into a collaborative research
agreement with IVEX to optimise the design of AAV vector delivery
methods for anti-aging therapies based on Sirtuin-6, a gene variant
that is found in centenarians shown to have significant
capabilities to repair DNA damage contributing to aging, and for
the large-scale production of AAV vectors for in vivo study in
animal models.
As part of the funded programme, Genflow and IVEX intend to
create precise tools to evaluate the effect of Genflow's gene
therapy drug candidates at unseen resolutions and precision levels
which will likely optimise gene delivery and improve gene
therapies.
Additionally, the Company envisions that the anti-aging gene
therapy platform being developed promises a significant reduction
of animal studies and will determine the optimal drug dose and
formulation prior to the start of clinical trials. Furthermore, the
project will seek to develop a series of alternative novel gene
therapy platforms in collaboration with the University of Tartu for
the precise delivery of a candidate drug. The initial results are
anticipated to be released in Q3 2023.
The Company believes that the non-dilutive grant received by
IVEX from Enterprise Estonia will support the acceleration of the
project's development of anti-aging gene therapies and expedite
Genflow's drug development programme.
Genflow is a UK-based biotechnology company focused on longevity
and the development of therapies to counteract the effects of aging
and diseases associated with advanced age.
Dr Eric Leire, Founder and CEO of Genflow , said: "We are
delighted and honored by the Estonian government's decision to
award this grant to the research programme Genflow is conducting in
collaboration with IVEX Lab . The grant will enhance Genflow's
future therapeutic developments and boost the Company's
pre-clinical drug discovery and research initiatives, aimed at
assisting people to live longer, healthier lives . I congratulate
the Genflow team and IVEX Lab for obtaining this encouraging
financing, which confirms confidence in the ant-aging science
underpinning our business and our long-term goals."
Illar Pata, Chief Executive Officer and Owner of IVEX Lab OÜ ,
said: "Our greatest asset in the field of gene therapy vehicle
development is the clear understanding about the specificity and
efficiency of therapeutic gene expression. The grant is supporting
IVEX Lab OÜ to develop the preclinical platform for the precise
assessment of drug candidates and their therapeutic
performance."
For further information please contact:
Genflow Biosciences Plc
Dr Eric Leire via Tancredi +44 203 434
Chief Executive 2330
------------------------------
Clear Capital Markets Ltd
------------------------------
Corporate Broker
Jonathan Critchley +44 203 869 6086
Keith Swann +44 203 897 0981
------------------------------
Tancredi Intelligent Communication
Media Relations
------------------------------
Salamander Davoudi +44 7957 549 906
Helen Humphrey +44 7449 226 720
Benedetta Negri da Oleggio +44 7838 029 970
genflowbio@tancredigroup.com
------------------------------
About Genflow
Genflow is a UK-based biotechnology company established in 2020.
The Company is developing gene therapies designed to target the
aging process and to reduce and delay the incidence of age-related
diseases. This will be done through novel therapeutics targeting
aging in humans by using adeno associated virus ("AAV") vectors to
deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is
found in centenarians into cells.
Its mission is to increase understanding of the factors that
control and impact lifespan. Genflow researches, develops, and
commercialises therapeutic solutions to lengthen health span, the
amount of time we live in good health, creating biological
interventions that enable longer and healthier lives. Genflow is
dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging,
Genflow can contribute to a decrease in healthcare costs and lessen
the emotional and societal burden that comes with an aging
population.
To learn more visit www.genflowbio.com
-Ends-
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBKDBKKBDKQKD
(END) Dow Jones Newswires
October 11, 2022 02:00 ET (06:00 GMT)
Genflow Biosciences (LSE:GENF)
Historical Stock Chart
From Apr 2024 to May 2024
Genflow Biosciences (LSE:GENF)
Historical Stock Chart
From May 2023 to May 2024